Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)

Overview

Journal Dermatol Ther (Heidelb)

Date 2024 May 2

PMID 38696027

Authors

Eric L Simpson

Vimal H Prajapati

Yael A Leshem

Raj Chovatiya

Marjolein S de Bruin-Weller

Sonja Stander

Andrew E Pink

Brian M Calimlim

Wan-Ju Lee

Henrique Teixeira

Barry Ladizinski

Xiaofei Hu

Yang Yang

Yingyi Liu

Meng Liu

Ayman Grada

Andrew M Platt

Jonathan I Silverberg

Affiliations

Soon will be listed here.

Abstract

Introduction: Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus kinase inhibitor) monotherapy on patient-reported outcomes (PROs) among adults and adolescents with moderate-to-severe AD over 16 weeks.

Methods: This integrated analysis of the double-blind, placebo-controlled periods of phase 3 monotherapy clinical trials Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422) assessed itch (Worst Pruritus Numerical Rating Scale [WP-NRS] and SCORing Atopic Dermatitis [SCORAD]), skin pain and symptom severity (AD Symptom Scale), symptom frequency (Patient-Oriented Eczema Measure), sleep (AD Impact Scale [ADerm-IS] and SCORAD), daily activities and emotional state (ADerm-IS), QoL (Dermatology Life Quality Index [DLQI] and Children's DLQI), mental health (Hospital Anxiety and Depression Scale), and patient impressions (Patient Global Impression of Severity, Patient Global Impression of Change, and Patient Global Impression of Treatment).

Results: Data from 1683 patients (upadacitinib 15 mg, n = 557; upadacitinib 30 mg, n = 567; placebo, n = 559) were analyzed. A greater proportion of patients receiving upadacitinib versus placebo experienced improvements in itch (≥ 4-point improvement on WP-NRS) by week 1 (upadacitinib 15 mg, 11.2%; upadacitinib 30 mg, 17.7%; placebo, 0.5%; P < 0.001), with response rates sustained through week 16 (upadacitinib 15 mg, 47.1%; upadacitinib 30 mg, 59.8%; placebo, 10.4%; P < 0.001). Improvements were similar for PROs assessing skin pain/symptoms, sleep, daily activities, QoL, emotional state, mental health, and patient impressions of disease severity and treatment. Responses generally improved rapidly (within 1-2 weeks), increased through weeks 4-6, and were maintained through week 16.

Conclusions: Once-daily oral upadacitinib monotherapy improved response rates across PROs compared with placebo. Upadacitinib therapy resulted in rapid, sustained improvements in PROs measuring symptom burden and QoL in adults and adolescents with moderate-to-severe AD.

Trial Registration: ClinicalTrials.gov identifiers, NCT03569293 and NCT03607422.

References

de Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G . Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. Acta Derm Venereol. 2021; 101(2):adv00402. PMC: 9366686. DOI: 10.2340/00015555-3751. View

von Kobyletzki L, Thomas K, Schmitt J, Chalmers J, Deckert S, Aoki V . What Factors are Important to Patients when Assessing Treatment Response: An International Cross-sectional Survey. Acta Derm Venereol. 2016; 97(1):86-90. DOI: 10.2340/00015555-2480. View

Copley-Merriman C, Zelt S, Clark M, Gnanasakthy A . Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development. Patient. 2016; 10(2):203-213. DOI: 10.1007/s40271-016-0196-6. View

Parmentier J, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M . In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2019; 2:23. PMC: 6390583. DOI: 10.1186/s41927-018-0031-x. View

Augustin M, Langenbruch A, Blome C, Gutknecht M, Werfel T, Stander S . Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2019; 34(1):142-152. DOI: 10.1111/jdv.15919. View

Simpson E, Papp K, Blauvelt A, Chu C, Hong H, Katoh N . Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022; 158(4):404-413. PMC: 8908226. DOI: 10.1001/jamadermatol.2022.0029. View

Guttman-Yassky E, Thaci D, Pangan A, Hong H, Papp K, Reich K . Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2019; 145(3):877-884. DOI: 10.1016/j.jaci.2019.11.025. View

Silverberg J, Barbarot S, Gadkari A, Simpson E, Weidinger S, Mina-Osorio P . Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021; 126(4):417-428.e2. DOI: 10.1016/j.anai.2020.12.020. View

de Bruin-Weller M, Deleuran M, Biedermann T, Bissonnette R, Foley P, Girolomoni G . The Treat-to-Target Project in Atopic Dermatitis: One Year On. Acta Derm Venereol. 2023; 103:adv5382. PMC: 10134065. DOI: 10.2340/actadv.v103.5382. View

10.

Ronnstad A, Halling-Overgaard A, Hamann C, Skov L, Egeberg A, Thyssen J . Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol. 2018; 79(3):448-456.e30. DOI: 10.1016/j.jaad.2018.03.017. View

11.

Foley C, Tundia N, Simpson E, Teixeira H, Litcher-Kelly L, Bodhani A . Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). Curr Med Res Opin. 2018; 35(7):1139-1148. DOI: 10.1080/03007995.2018.1560222. View

12.

Guttman-Yassky E, Teixeira H, Simpson E, Papp K, Pangan A, Blauvelt A . Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021; 397(10290):2151-2168. DOI: 10.1016/S0140-6736(21)00588-2. View

13.

Drucker A . Atopic dermatitis: Burden of illness, quality of life, and associated complications. Allergy Asthma Proc. 2017; 38(1):3-8. DOI: 10.2500/aap.2017.38.4005. View

14.

Leshem Y, Chalmers J, Apfelbacher C, Furue M, Gerbens L, Prinsen C . Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. J Am Acad Dermatol. 2020; 82(5):1181-1186. DOI: 10.1016/j.jaad.2019.12.055. View

15.

Silverberg J, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Costanzo A . Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. J Allergy Clin Immunol. 2021; 149(3):977-987.e14. DOI: 10.1016/j.jaci.2021.07.036. View

16.

Laughter M, Maymone M, Mashayekhi S, Arents B, Karimkhani C, Langan S . The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017. Br J Dermatol. 2020; 184(2):304-309. DOI: 10.1111/bjd.19580. View

17.

Reich K, Teixeira H, de Bruin-Weller M, Bieber T, Soong W, Kabashima K . Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10290):2169-2181. DOI: 10.1016/S0140-6736(21)00589-4. View

18.

Bawany F, Northcott C, Beck L, Pigeon W . Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies. J Allergy Clin Immunol Pract. 2020; 9(4):1488-1500. PMC: 9026738. DOI: 10.1016/j.jaip.2020.12.007. View

19.

Silverberg J, Chiesa-Fuxench Z, Margolis D, Boguniewicz M, Fonacier L, Grayson M . Epidemiology and Burden of Sleep Disturbances in Atopic Dermatitis in US Adults. Dermatitis. 2021; 33(6S):S104-S113. DOI: 10.1097/DER.0000000000000731. View

20.

Williams H, Schmitt J, Thomas K, Spuls P, Simpson E, Apfelbacher C . The HOME Core outcome set for clinical trials of atopic dermatitis. J Allergy Clin Immunol. 2022; 149(6):1899-1911. DOI: 10.1016/j.jaci.2022.03.017. View